Clinical trials: Chronic Obstructive Pulmonary
Pulmonary Disease, Chronic Obstructive
Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease
The objective of this study is to demonstrate that, when added to tiotropium (TIO), fluticasone propionate/salmeterol combination (FSC) DISKUS 250/50 significantly increases exercise endurance time (EET) in the endurance shuttle…
- Trial name
- ESWT (NCT01124422)
- Testing
- fluticasone propionate/salmeterol inhalation powder DISKUS 250/50, tiotropium bromide inhalation powder HandiHaler
- Where
- 27 sites in United States, Canada
- Volunteers
- 255 people
- Sponsor
- GlaxoSmithKline
Hematological Malignancies
Rituximab for Prevention of Chronic GVHD
The purpose of this trial is to determine if administration of rituximab after allogeneic stem cell transplantation can reduce the incidence of chronic GVHD.
- Trial name
- NCT00379587
- Testing
- Rituximab, 375 mg/m2 RRituximab
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Dana-Farber Cancer Institute
Chronic Obstructive Pulmonary Disease
Differentiating the Effects of Substance P and Beta-endorphin
In previous studies we demonstrated that endogenous opioids (inhibitory neuropeptides) modulate the perception of breathing difficulty in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01854177
- Testing
- Aprepitant
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Pulmonary Disease, Chronic Obstructive
Comparative Study of ELLIPTA Dry Powder Inhaler (DPI) Versus DISKUS DPI Used With HandiHaler DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This randomized, cross over study aims to find out the benefits of delivering triple therapy using a single ELLIPTA® DPI (fixed-dose combination triple therapy) versus delivering triple therapy using two different types of…
- Trial name
- NCT03227445
- Testing
- Inhaler preference questionnaires
- Where
- 18 sites in United States
- Volunteers
- 240 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Ventilator Adapters for Combivent Respimat
The general aim of this 1-day, open label, non-randomised, trial is to characterize the performance of two adapter devices designed to permit use of the Respimat® inhaler with patients requiring mechanical ventilation.
- Trial name
- NCT01969539
- Testing
- Combivent Respimat via tee adapter, Combivent Respimat via ventilator adapter
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Boehringer Ingelheim
COPD
A Proof of Concept Study to Evaluate the Dose Response for the Systemic Benefit Risk Ratio of Inhaled Fluticasone Propionate in Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD) is a major worldwide problem.Steroids inhalers are now an established treatment for COPD.
- Trial name
- NCT00995475
- Testing
- Fluticasone propionate
- Volunteers
- 18 people
- Sponsor
- University of Dundee
Asthma, Rhinitis
Study of Asthma and Nasal Steroids
The trial will study the effectiveness of nasal steroids for the treatment of chronic rhinitis and/or sinusitis on asthma control.
- Conditions
- Asthma, Rhinitis, Sinusitis
- Trial name
- STAN (NCT01118312)
- Testing
- Mometasone Furoate monohydrate
- Where
- 19 sites in United States
- Volunteers
- 388 people
- Sponsor
- JHSPH Center for Clinical Trials
Lung Diseases, Pulmonary Disease, Chronic Obstructive
An Investigational Drug Study In Patients With COPD (Chronic Obstructive Pulmonary Disease) (MK-0873-005)
This is a study to evaluate the effectiveness and tolerability of a once-daily oral medication (MK-0873) for the treatment of COPD (chronic obstructive pulmonary disease) to determine whether the study drug leads to an…
- Trial name
- NCT00132730
- Testing
- MK-0873 2.5 mg, MK-0873 1.25 mg, MK-0873 0.75 mg
- Volunteers
- 604 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Obstructive Pulmonary Disease
Study to Evaluate the Safety and Efficacy of Formoterol in a Daily Dose of 18 µg (9 µg Twice Daily) in Japanese Chronic Obstructive Pulmonary Disease (COPD) Patients
This study is a multicentre, open, randomised, parallel-group study with formoterol 9 μg one inhalation b.i.d, or standard COPD therapy.
- Trial name
- NCT01047553
- Testing
- Formoterol (OT)
- Where
- 27 sites in Japan
- Volunteers
- 251 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo
A study to assess the safety, tolerability and efficacy of NVA237 versus placebo in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
- Trial name
- GLOW 1 (NCT01005901)
- Testing
- Glycopyrronium bromide
- Where
- 96 sites in United States, Australia and 9 more
- Volunteers
- 1,324 people
- Sponsor
- Novartis
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Comparative Effectiveness of Telemedicine in Primary Care
Leveraging a natural experiment approach, the investigators will examine rapidly changing telemedicine and in-person models of care during and after the COVID-19 crisis to determine whether certain patients could safely choose to…
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure, Diabetes
- Trial name
- NCT04684836
- Testing
- Exposure to telemedicine, after the onset of the pandemic
- Where
- 4 sites in United States
- Volunteers
- 33,100 people
- Sponsor
- Weill Medical College of Cornell University
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL administered with 5 microgram tiotropium bromide solution for inhalation, delivered by the Respimat® inhaler, once daily for four weeks in…
- Trial name
- NCT00720499
- Testing
- BI 1744 CL plus tiotropium bromide, Respimat® Inhaler
- Where
- 24 sites in United States, Belgium and 2 more
- Volunteers
- 141 people
- Sponsor
- Boehringer Ingelheim
Chronic Graft-versus-host Disease
GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
The purpose of this study is to assess the efficacy and safety of itacitinib in combination with corticosteroids as first-line treatment for moderate or severe chronic graft-versus-host disease (cGVHD).
- Trial name
- NCT03584516
- Testing
- Itacitinib, Methylprednisolone, Prednisone
- Where
- 133 sites in United States, Austria and 14 more
- Volunteers
- 155 people
- Sponsor
- Incyte Corporation
Pulmonary Disease, Chronic Obstructive
Venovenous CO2 Removal (VVCO2R) in Patients With COPD and Acute Respiratory Failure
The purpose of this study to determine the safety and effectiveness of a mechanical device to remove carbon dioxide from the blood of patients with chronic obstructive pulmonary disease (COPD)when they are hospitalized in the…
- Trial name
- VVCO2R (NCT00594009)
- Testing
- Venovenous CO2 Removal (VVCO2R) in COPD
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Pulmonary Disease, Chronic Obstructive
Fixed Dose Combination Versus Free Combination of Tiotropium and Olodaterol in COPD
This is a 4-week, multicenter, randomized, double-blind, parallel group and active controlled study. Patients will be randomized (1 to 1 ratio) to a 4-week double-blind treatment period of either FDC (fixed-dose combination) of…
- Trial name
- NCT02683109
- Testing
- FDC of tiotropium + olodaterol, Tiotropium, Olodaterol
- Where
- 22 sites in Austria, Denmark and 3 more
- Volunteers
- 221 people
- Sponsor
- Boehringer Ingelheim
Psoriasis, Skin Diseases
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
This is a dose-ranging study designed to investigate the efficacy and safety of Baricitinib in the treatment of participants with moderate to severe, chronic plaque psoriasis as assessed by the Psoriasis Area and Severity Index…
- Conditions
- Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous
- Trial name
- NCT01490632
- Testing
- Baricitinib
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 271 people
- Sponsor
- Eli Lilly and Company
Pulmonary Disease, Chronic Obstructive
Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients
The objective of the trial is to compare the lung function profile of once daily treatment with tiotropium+olodaterol FDC [2.5/ 5µg and 5/ 5µg] delivered by the RESPIMAT with the lung function profile of twice daily treatment…
- Trial name
- NCT01969721
- Testing
- fluticasone propionate, salmeterol, tiotropium
- Where
- 29 sites in Belgium, Czechia and 6 more
- Volunteers
- 229 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Safety, Tolerability and Pharmacokinetics and Effect on Inflammation of Oral BI 1026706 in Patients With COPD
The main objective of the current trial is to investigate safety, tolerability, pharmacokinetics and effect on inflammation of oral BI 1026706 administered twice daily for 4 weeks in patients with COPD.
- Trial name
- NCT02642614
- Testing
- BI 1026706
- Where
- 10 sites in Denmark, Germany and 2 more
- Volunteers
- 120 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Physical Training and Heart Rate Variability in COPD
To contrast the potential effects of physical exercise training program (PTP) of a 6 versus 12 weeks on cardiac autonomic modulation by linear and non-linear heart rate variability (HRV) indices and functional capacity in…
- Trial name
- NCT01889563
- Testing
- Physical Exercise Training Program Exercise
- Where
- Brazil
- Volunteers
- 32 people
- Sponsor
- Universidade Federal de Sao Carlos
COPD, Chronic Obstructive Pulmonary Disease
A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease
The purpose of this study is to evaluate the dose-response of different doses of CHF 5259 pMDI on lung function and other clinical outcomes, to identify the optimal dose(s) in terms of benefit/ risk ratio for further development…
- Trial name
- GLIMMER (NCT03084796)
- Testing
- CHF 5259, Tiotropium Bromide 18 µg Inhalation Capsule
- Where
- 112 sites in United States
- Volunteers
- 733 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.